Logotype for Vera Therapeutics Inc

Vera Therapeutics (VERA) investor relations material

Vera Therapeutics Cantor Global Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Vera Therapeutics Inc
Cantor Global Healthcare Conference 2025 summary4 Sep, 2025

Key clinical developments

  • Lead product Atacicept showed strong results in Phase III for IgA nephropathy, with plans to file a BLA in Q4 and anticipated market entry by mid-next year.

  • Phase II and III data demonstrated consistent efficacy, including a 42% placebo-adjusted reduction in proteinuria and stabilization of GFR, surpassing FDA thresholds.

  • Long-term data showed patients on Atacicept could avoid dialysis or transplant, marking a transformative advance in kidney disease management.

  • Open-label extension studies are ongoing, with high patient enthusiasm and positive real-world experience using the auto-injector.

  • Monthly dosing studies and a new fusion protein (VT-109) are in progress to expand the product profile and dosing flexibility.

Market opportunity and commercialization

  • IgA nephropathy is a significant unmet need, with an estimated 160,000–200,000 US patients and a potential $10–20 billion market.

  • Diagnosis rates are expected to rise as new therapies become available, expanding the addressable market.

  • Commercial launch preparations are advanced, with sales leadership in place and strong engagement with the nephrology and patient communities.

  • The auto-injector is well received, offering convenient at-home administration and high patient retention over two years.

  • The company is leveraging synergies across clinical sites and capital efficiency for ongoing and future studies.

Regulatory and competitive landscape

  • BLA submission is on track for Q4, with no major gating factors and expectations for priority review.

  • Regulatory discussions are collaborative, and there is optimism for a competitive label based on the unique mechanism and robust data.

  • The company is closely monitoring competitor data but remains confident in its differentiated results and future market position.

  • Additional studies (PIONEER) are enrolling broader IgAN populations and exploring other autoimmune kidney diseases.

  • The pipeline includes plans to expand into membranous nephropathy, FSGS, MCD, and potentially other autoimmune indications.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Vera Therapeutics earnings date

Logotype for Vera Therapeutics Inc
Q3 20257 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Vera Therapeutics earnings date

Logotype for Vera Therapeutics Inc
Q3 20257 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Vera Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing and commercializing treatments aimed at serious immunological diseases. Their portfolio includes atacicept, a fusion protein undergoing clinical trials for immunoglobulin A nephropathy and Phase II trials for lupus nephritis. Another significant development in their pipeline is MAU868, a monoclonal antibody targeting the BK virus in transplant patients. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage